We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


AnaSpec Expands SensoLyte® 520 Renin Assay Kits Collection

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Expands SensoLyte® 520 Renin Assay Kits Collection"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaSpec, the provider of the ultra-sensitive SensoLyte® 520 Human Renin Assay Kit now provides renin kits specific for mouse and rat - the SensoLyte® 520 Mouse Renin Assay Kit and SensoLyte® 520 Rat Renin Assay Kit.

Using our proprietary 5-FAM/QXL™ 520 fluorescence resonance energy transfer (FRET) peptide, all three assays are ideal for screening of renin inhibitors and for continuous assay of renin activity, especially for high throughput screening (HTS) purposes.

In the intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL™ 520. However, upon cleavage into two separate fragments by rat renin, the fluorescence of 5-FAM is recovered, and can be monitored at excitation/emission = 490/520 nm.

With a high fluorescence quantum yield and long emission wavelength, the signal of 5-FAM can be detected with less interference from the auto fluorescence of cell components and test compounds.

The assays are performed in a convenient 96-well microplate format and can be adjusted to 384-well microplate format.

Key characteristics for SensoLyte® 520 Renin Assay Kits are ultra-sensitive, detects long wavelength and minimal autoflorescence, with FRET based substrates, and specific for human, mouse and rat.

The renin-angiotensin system (RAS) plays a central role in the regulation of blood pressure and electrolyte homoeostasis.

At the first and rate-limiting step of the RAS cascade, renin, a highly specific aspartyl protease, cleaves angiotensinogen, produced in the liver, to yield angiotensin I, which is further converted into angiotensin II by ACE (Angiotensin Converting Enzyme). Angiotensin II constricts blood vessels leading to increased blood pressure.

It also increases the secretion of ADH and aldosterone, and stimulates the hypothalamus to activate the thirst reflex.

Since an overactive renin-angiotensin system leads to hypertension, renin is an attractive target for the treatment of this disease.